Journal for ImmunoTherapy of Cancer (JITC) is a leading open-access, peer-reviewed journal exclusively focused on the latest advancements in cancer immunotherapy. JITC publishes high-quality research articles, reviews, and perspectives that span the breadth of the field, from preclinical studies to clinical trials and translational research.
The journal's scope encompasses various immunotherapy approaches, including checkpoint inhibitors, CAR T-cell therapy, oncolytic viruses, cancer vaccines, and other innovative strategies aimed at harnessing the power of the immune system to fight cancer. JITC places a strong emphasis on studies that demonstrate clinical efficacy, biomarker discovery, and mechanisms of action. Indexed in major databases, JITC is essential reading for oncologists, immunologists, researchers, and clinicians.
By providing a dedicated forum for the exchange of ideas and the dissemination of groundbreaking findings, JITC strives to accelerate the development and implementation of effective immunotherapeutic strategies for cancer patients worldwide. The journal encourages submissions that push the boundaries of knowledge and offer hope for improved outcomes in the fight against this disease. JITC is the official journal of the Society for Immunotherapy of Cancer (SITC).